share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股sec公告 ·  06/27 08:03
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of June 2024. On June 26, 2024, the company amended two warrants with a certain institutional investor. The first amendment pertains to a 2023 Warrant initially issued in June 2023, which has been modified to adjust the 'Redemption Right' and extend its termination date to October 12, 2029. The second amendment extends the termination date of a 2024 Warrant, issued in April 2024, also to October 12, 2029. These amendments are detailed in Exhibits 10.1 and 10.2 attached to the Form 6-K report. The report also states that it will be incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3.
NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of June 2024. On June 26, 2024, the company amended two warrants with a certain institutional investor. The first amendment pertains to a 2023 Warrant initially issued in June 2023, which has been modified to adjust the 'Redemption Right' and extend its termination date to October 12, 2029. The second amendment extends the termination date of a 2024 Warrant, issued in April 2024, also to October 12, 2029. These amendments are detailed in Exhibits 10.1 and 10.2 attached to the Form 6-K report. The report also states that it will be incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3.
NeuroSense Therapeutics Ltd.,一家外國私人發行人,已向美國證券交易委員會(SEC)提交了2024年6月份的報告。2024年6月26日,該公司與某機構投資者修改了兩項認股權證。第一個修正涉及2023年6月最初發行的認股權證,已調整“贖回權”,並將其終止日期延長至2029年10月12日。第二個修正將2024年4月發行的認股權證的終止日期也延長至2029年10月12日。這些修改的詳細信息在提交的6-K表格中的附件10.1和10.2中詳細說明。該報告還指出,它將作爲參考納入公司現有的S-8和F-3表格的註冊聲明中。
NeuroSense Therapeutics Ltd.,一家外國私人發行人,已向美國證券交易委員會(SEC)提交了2024年6月份的報告。2024年6月26日,該公司與某機構投資者修改了兩項認股權證。第一個修正涉及2023年6月最初發行的認股權證,已調整“贖回權”,並將其終止日期延長至2029年10月12日。第二個修正將2024年4月發行的認股權證的終止日期也延長至2029年10月12日。這些修改的詳細信息在提交的6-K表格中的附件10.1和10.2中詳細說明。該報告還指出,它將作爲參考納入公司現有的S-8和F-3表格的註冊聲明中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息